Please login to the form below

Not currently logged in
Email:
Password:

Tresiba

This page shows the latest Tresiba news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk preps for speedy oral GLP-1 drug filing

Novo Nordisk preps for speedy oral GLP-1 drug filing

10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone.

Latest news

More from news
Approximately 29 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations.

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba (insulin degludec), which was approved in Europe at the ... Tresiba has also demonstrated it is just as effective even when

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...